Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
- Revenue in USD (TTM)0.00
- Net income in USD-42.55m
- Incorporated2018
- Employees56.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treace Medical Concepts Inc | 196.03m | -54.75m | 310.04m | 516.00 | -- | 2.45 | -- | 1.58 | -0.8885 | -0.8885 | 3.18 | 2.04 | 0.797 | 1.28 | 7.07 | 379,905.00 | -22.26 | -- | -25.98 | -- | 80.99 | -- | -27.93 | -- | 3.22 | -- | 0.2958 | -- | 31.92 | -- | -15.68 | -- | -- | -- |
| Tactile Systems Technology Inc | 276.67m | 28.19m | 326.25m | 992.00 | 11.61 | 1.69 | 9.39 | 1.18 | 1.18 | 1.18 | 11.70 | 8.14 | 1.01 | 6.77 | 6.05 | 278,896.20 | 10.30 | 0.9015 | 12.18 | 1.09 | 49.98 | 49.10 | 10.19 | 0.8309 | 3.63 | -- | 0.128 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Zynex Inc | 188.68m | 8.17m | 345.71m | 1.10k | 48.12 | 10.64 | 27.33 | 1.83 | 0.2261 | 0.2261 | 5.39 | 1.02 | 1.59 | 2.52 | 6.56 | 171,530.00 | 6.89 | 14.58 | 8.41 | 17.52 | 80.22 | 79.62 | 4.33 | 10.44 | 2.87 | 7.24 | 0.6381 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Pulmonx Corp | 72.99m | -58.73m | 349.34m | 279.00 | -- | 3.16 | -- | 4.79 | -1.54 | -1.54 | 1.91 | 2.85 | 0.399 | 1.14 | 7.81 | 261,627.20 | -32.11 | -26.27 | -35.87 | -28.97 | 74.31 | 71.95 | -80.46 | -93.76 | 6.14 | -- | 0.252 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Nevro Corp | 430.75m | -82.59m | 418.71m | 1.22k | -- | 1.50 | -- | 0.972 | -2.28 | -2.28 | 11.90 | 7.59 | 0.736 | 1.14 | 6.04 | 354,523.50 | -14.11 | -13.64 | -16.06 | -16.68 | 68.94 | 68.54 | -19.17 | -20.67 | 5.57 | -- | 0.4354 | -- | 4.63 | 1.88 | -3,172.74 | -- | 0.9012 | -- |
| Pulse Biosciences Inc | 0.00 | -42.55m | 431.31m | 56.00 | -- | 11.89 | -- | -- | -0.8152 | -0.8152 | 0.00 | 0.6571 | 0.00 | -- | -- | 0.00 | -71.28 | -93.21 | -79.29 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Heart Test Laboratories Inc | 18.60k | -6.39m | 456.96m | 12.00 | -- | 51.36 | -- | 24,567.99 | -0.4912 | -0.4912 | 0.0009 | 0.1357 | 0.0026 | 0.009 | 2.53 | 1,550.00 | -89.51 | -- | -120.71 | -- | 67.31 | -- | -34,362.42 | -- | 4.70 | -16.41 | 0.0547 | -- | -64.16 | -- | -31.61 | -- | -- | -- |
| ZimVie Inc | 455.22m | -51.16m | 464.45m | 2.60k | -- | 1.20 | -- | 1.02 | -1.92 | -14.01 | 17.11 | 14.24 | 0.3299 | 1.09 | 3.73 | 175,085.40 | -3.71 | -- | -4.28 | -- | 63.05 | 65.51 | -11.24 | -8.73 | 2.23 | -0.343 | 0.5673 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Jin Medical International Ltd | 19.98m | 3.25m | 469.64m | 269.00 | 134.41 | 19.75 | 131.24 | 23.51 | 0.0223 | 0.0223 | 0.1353 | 0.1519 | 0.7557 | 1.85 | 5.00 | 74,260.52 | 12.28 | -- | 16.62 | -- | 33.02 | -- | 16.25 | -- | 3.02 | -- | 0.0582 | -- | -7.58 | -- | 2.84 | -- | -- | -- |
| MaxCyte Inc | 44.05m | -36.57m | 488.22m | 143.00 | -- | 2.15 | -- | 11.08 | -0.3532 | -0.3532 | 0.4253 | 2.17 | 0.1633 | 0.463 | 5.77 | 308,067.80 | -13.56 | -13.18 | -14.36 | -14.33 | 88.32 | 88.79 | -83.01 | -62.96 | 12.37 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Surmodics Inc | 142.96m | 13.50m | 493.68m | 376.00 | 36.07 | 3.98 | 22.20 | 3.45 | 0.9597 | 0.9597 | 10.14 | 8.69 | 0.8194 | 2.05 | 6.66 | 380,220.80 | 7.74 | -1.85 | 8.69 | -2.18 | 79.11 | 82.93 | 9.44 | -2.98 | 3.59 | 9.66 | 0.1921 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Bioventus Inc | 522.74m | -21.65m | 507.94m | 995.00 | -- | 2.96 | 19.91 | 0.9717 | -0.3438 | -0.3438 | 8.30 | 2.16 | 0.6217 | 1.95 | 4.28 | 538,910.30 | -3.23 | -5.52 | -4.47 | -7.27 | 65.55 | 68.25 | -5.20 | -10.94 | 0.9745 | 1.03 | 0.6428 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Iradimed Corp | 67.69m | 17.92m | 532.28m | 148.00 | 29.87 | 6.99 | 28.42 | 7.86 | 1.41 | 1.41 | 5.31 | 6.01 | 0.8273 | 1.67 | 5.51 | 457,333.40 | 21.91 | 13.16 | 24.02 | 14.58 | 76.57 | 76.55 | 26.48 | 21.46 | 7.77 | -- | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| Pacific Biosciences of California Inc | 200.43m | -296.90m | 550.13m | 796.00 | -- | 0.8474 | -- | 2.74 | -1.14 | -1.14 | 0.7695 | 2.38 | 0.1124 | 2.21 | 6.69 | 251,797.70 | -16.65 | -16.19 | -18.40 | -17.81 | 28.81 | 37.35 | -148.13 | -136.21 | 8.36 | -21.84 | 0.5791 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Orthofix Medical Inc | 760.05m | -126.48m | 562.94m | 1.63k | -- | 0.9839 | -- | 0.7407 | -3.40 | -3.40 | 20.42 | 15.24 | 0.8338 | 1.16 | 6.36 | 465,143.80 | -13.87 | -8.88 | -16.48 | -10.96 | 66.20 | 72.37 | -16.64 | -9.28 | 1.19 | -8.38 | 0.194 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Nano-X Imaging Ltd | 9.91m | -60.78m | 566.33m | 164.00 | -- | 2.90 | -- | 57.18 | -1.08 | -1.08 | 0.1757 | 3.38 | 0.0419 | -- | 8.05 | 60,396.34 | -25.72 | -30.98 | -28.14 | -35.10 | -66.55 | -- | -613.59 | -1,527.24 | 5.56 | -- | 0.0175 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
Data as of May 17 2024. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD
7.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 956.33k | 1.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 827.67k | 1.50% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 777.13k | 1.41% |
| Geode Capital Management LLCas of 31 Mar 2024 | 390.96k | 0.71% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 349.74k | 0.63% |
| Griffin Asset Management, Inc.as of 31 Mar 2024 | 300.32k | 0.54% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 187.14k | 0.34% |
| Spotlight Asset Group, Inc.as of 31 Mar 2024 | 72.09k | 0.13% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 61.40k | 0.11% |
| Citadel Securities LLCas of 31 Mar 2024 | 54.08k | 0.10% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
